LNTHNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Lantheus Holdings, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$99.92+0.22 (+0.22%)
Close on Oct 19, 2026
- Market cap
- $6.75B
- P/E (TTM)
- 24.2
- Dividend yield
- –
Lantheus Holdings, Inc. revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| International | – | – | – | – | – | $44.61M | $43.35M | $54.79M | $41.38M | $44.43M | – | – |
| U.S. | – | – | – | – | – | $294.80M | $303.99M | $288.58M | $290.00M | $257.42M | – | – |
| Worldwide | – | – | – | – | – | – | $347.34M | $343.37M | $331.38M | – | – | – |
| Operating income | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| International | – | – | – | – | – | $6.17M | $7.39M | $8.16M | $2.61M | $9.68M | – |
| U.S. | – | – | – | – | – | -$10.36M | $44.28M | $56.33M | $49.24M | $46.91M | – |
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product revenue, net | $1.51B | $1.52B | $1.26B | $887.04M | $400.36M | – | – | – | – | – | 97.8% | -1.1% |
| Total radiopharmaceutical oncology | $989.12M | $1.06B | $854.43M | $531.51M | $48.89M | $10.02M | $8.66M | – | – | – | 64.2% | -6.5% |
| PYLARIFY | $989.12M | $1.06B | $851.30M | $527.41M | $43.41M | $0 | $0 | – | – | – | 64.2% | -6.5% |
| Total precision diagnostics | $493.11M | $437.51M | $390.12M | $356.68M | $351.03M | $317.63M | $337.11M | – | – | – | 32.0% | +12.7% |
| DEFINITY | $330.25M | $317.79M | $279.77M | $244.99M | $232.76M | $195.87M | $202.40M | $183.07M | $157.27M | $131.61M | 21.4% | +3.9% |
| Techne Lite | $86.80M | $95.49M | $87.37M | $88.86M | $91.29M | $84.95M | $85.47M | $98.86M | $104.64M | $99.22M | 5.6% | -9.1% |
| Strategic partnerships and other revenue | $59.38M | $38.18M | $51.88M | $46.87M | $25.30M | $11.75M | $1.58M | – | – | – | 3.9% | +55.5% |
| Neuraceq | $51.45M | $0 | $0 | – | – | – | – | – | – | – | 3.3% | – |
| License and royalty revenues | $34.04M | $9.13M | $33.36M | $48.02M | $24.85M | $11.72M | $2.06M | $2.24M | – | – | 2.2% | +272.9% |
| Other precision diagnostics | $24.62M | $24.23M | $22.98M | $22.83M | $26.97M | $36.82M | $49.24M | – | – | – | 1.6% | +1.6% |
| Other radiopharmaceutical oncology | $0 | $384.00K | $3.13M | $4.10M | $5.47M | $10.02M | $8.66M | – | – | – | 0.0% | -100.0% |
| Xenon | – | – | – | – | – | – | – | – | $31.38M | $29.09M | – | – |
| Other | – | – | – | – | – | – | – | $61.44M | $69.47M | $71.02M | – | – |
| Product revenue, net | – | – | – | $887.04M | $400.36M | $327.70M | $345.28M | $341.14M | – | – | – | – |
| Other nuclear | – | – | – | – | – | $58.92M | $59.81M | $74.28M | – | – | – | – |
| Rebates and allowances | – | – | – | – | – | -$19.07M | -$16.57M | -$12.84M | – | – | – | – |
| License And Royalty Revenues Sales Based Milestone Payment | – | $0 | – | – | – | – | – | – | – | – | – | – |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $1.46B | $1.48B | $1.26B | – | – | – | – | $288.58M | $290.00M | $257.42M | 94.6% | -1.7% |
| Rest of world | $82.73M | $49.22M | $34.28M | – | – | – | – | – | – | – | 5.4% | +68.1% |
| Canada | – | – | – | – | – | – | – | – | $18.77M | $18.92M | – | – |
| All other | – | – | – | – | – | – | – | $54.79M | $41.38M | $44.43M | – | – |
From the segment and revenue-disaggregation notes of Lantheus's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.